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ABSTRACT
Objective: The objective of this selective evidence-based medicine (EBM) review is to
determine whether or not Tribulus terrestris is effective at increasing sexual desire in adult
women suffering from hypoactive sexual desire disorder (HSDD).
Study Design: Review of three randomized controlled trials published in 2014, 2016, and 2017;
selection was based on their relevance to the clinical question and on their patient-oriented
outcomes.
Data Sources: Three peer-reviewed primary studies comparing the use of Tribulus terrestris to
placebo in the treatment of HSDD were found on PubMed.
Outcome(s) Measured: For each trial, patients were divided into either Tribulus terrestris
treatment or placebo treatment groups. Trials assessed female sexual function index (FSFI) and
sexual quotient female (QS-F) questionnaire score improvements to evaluate treatment efficacy.
Results: All three trials used the FSFI questionnaire and reported a statistically significant (P <
0.05) increase in mean change from baseline in sexual desire when using Tribulus terrestris. De
Souza et al. and Vale et al. also reported a statistically significant (P < 0.05) increase in mean
change from baseline of the placebo group of < 0.01 and 0.001, respectively. De Souza et al. and
Vale et al. reported a statistically significant (P < 0.05) increase in sexual desire using QS-F results
with a number needed to treat (NNT) of 20 and 4, respectively.
Conclusion: Tribulus terrestris may safely and effectively improve sexual desire in women with
HSDD; however, clear and concise methods and statistical analysis are needed to further
investigate its full clinical potential.
Key Words: Hypoactive sexual desire disorder, Tribulus terrestris, female sexual dysfunction
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Introduction:
Sexual dysfunction is a worldwide disease burden that affects many individuals, with
significant accomplishments made thus far in the treatment, diagnosis, and pathophysiology of
male erectile dysfunction, premature ejaculation, and testosterone deficiency syndrome. However,
medical treatment and diagnosis of female sexual dysfunction to date still lag behind those of their
male counterparts, with emphasis placed on difficulty understanding the female sexual response.
The most prevalent sexual disorder affecting women is hypoactive sexual desire disorder (HSDD),
defined as a persistent dysfunction in desire and fantasy to engage in sexual behaviors that leads
to interpersonal distress not better explained by another condition.1 Distresses may include declines
in self-esteem, mental health, and emotional role fulfillment.
The sexual response is generally divided into four phases: desire, arousal, orgasm, and
resolution. Unfortunately, this model does not hold consistently true for all women because of the
multifactorial hormonal, neuronal, and psychosocial interactions that motivate female sexual
response. The biology of desire is poorly understood in women, but it is hypothesized that HSDD
is caused by some maladaptive neuronal process that precludes psychological priming for sex.2
HSDD affects approximately 10% of all adult women, although the annual incidence and
total healthcare cost of women seeking care for HSDD each year are currently unknown.3
However, from a 1998-2006 data analysis we do know women with HSDD international
classification of disease (ICD) diagnosis generally had higher healthcare expenditures compared
to those undiagnosed.3 Historically, women perceive more barriers to accessing healthcare for
sexual difficulties for a number of reasons, including cultural/societal norms, provider-based
knowledge, and personal embarrassment.4 In a survey conducted in 2009 with 3,239 women, only
34.5% had reported a sexual problem to their healthcare provider.4 HSDD is classified in the
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Diagnostic and Statistical Manual of Mental Disorders (5th ed.; DSM-5; American Psychiatric
Association, 2013) as part of Female Interest/Arousal Desire with diagnosis made on lack of
interest and arousal; however, no set analysis criteria or algorithm guides diagnosis and treatment.
This diagnostic ambiguity further promotes a lack of confidence in the healthcare system and
compounds the under-recognized healthcare-seeking and diagnostic behavior of women with
HSDD.
Current treatment options for women with HSDD include both pharmacotherapy and
psychotherapy. As of 2015, flibanserin was the only medication approved by the Food and Drug
Administration (FDA) for treating HSDD in perimenopausal women. Some off-label
pharmacological medications indicated for treatment are bupropion, sildenafil, buspirone,
esterified estrogen/methyltesterone, and testosterone transdermal patches.1 Psychotherapy options
include cognitive behavioral therapy, sensate focus, mindfulness training, and bibliotherapy.1
While all of these treatments may have shown beneficial effects for women at one point, they have
not been widely accepted in the clinical management of patients with HSDD.
Herbal supplements have long been used in various cultures to treat and cure diseases.
Tribulus terrestris is a plant native to Asia, Europe, and Africa and has long been endorsed
culturally for its possible aphrodisiac properties. Recent studies propose some validity to its ability
to mimic sex hormones for a natural option for women. The aim of this paper is to evaluate the
efficacy of Tribulus terrestris in increasing sexual desire in adult women older than 18 years of
age with HSDD by way of analyzing three double-blind randomized control trials.
Objective:
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The objective of this selective evidence-based medicine (EBM) review is to determine
whether Tribulus terrestris is effective at increasing sexual desire in adult women suffering from
HSDD.
Methods:
All three articles were researched using PubMed and were selected based on relevance to
the clinical question and their patient-oriented outcomes. The key words used to identify literature
included hypoactive sexual desire disorder, female sexual dysfunction, and Tribulus terrestris.
Three double-blind randomized placebo-controlled clinical trials were used in this
systematic review. All three studies required a population of adult women older than 18 years of
age with reported diminished libido. Table 1 displays the key characteristics and demographics of
the included studies. The intervention administered Tribulus terrestris orally to the experimental
group and a visually equivalent placebo to the control group. The outcome measured was
improvement in sexual desire. The statistics that were used and reported in all three studies were
mean changes from baseline, P values, ANOVA test, Wilcoxon test, and McNemar test.
Table 1: Demographics and Characteristics of Included Studies
Study

Type

# Pts

Age

Inclusion
Criteria

Exclusion Criteria

W/D

Interventions

Akhtari5
(2014)

Double Blind
RCT

67

36±7
years

Women of
childbearing
age, having
normal breast
exam, pelvic
exam, negative
pap smear,
married and
actively living
with a partner,
lack or loss of
libido causing
distress

7

Tribulus
terrestris extract
7.5mg/day

De Souza
KZ6
(2016)

Prospective
double-blind
RCT

45

43-65
years

Age between
1-10 yrs since
last menstrual
period, FSH

Lack of steady
sexual partner,
serious medical
condition, major
depression disorder
or other psychiatric
disorders, history of
genital tract or
breast cancers,
menopause,
pregnancy,
husband’s sexual
problems and active
plans for divorce
Used hormone or
drugs within
previous year,
smokers, had HTN,

9

Tribulus
terrestris 250 mg
TID orally
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level > 30,
estradiol level
< 40, body
mass index
less than 28

Vale7
(2017)

Double blind
RCT

64

18-44
years

Stable
relationship
for 2 yrs,
regular
menstrual
cycles,
diminished
libido

collagenosis,
unbalanced
endocrine system,
pulmonary, renal,
hepatic, vascular,
thromboembolic
disease, history of
endometrial cancer,
MI, oophorectomy,
partner with sexual
problems,
interpersonal
relationship
problems
Pregnant, on
hormonal
contraception,
regular/medications,
clinically depressed,
had HTN,
collagenosis,
unbalanced
endocrine system,
pulmonary, renal,
hepatic, vascular,
thromboembolic
disease, history of
endometrial cancer,
MI, partner with
sexual problems,
interpersonal
relationship
problems

24

Tribulus
terrestris 250 mg
TID orally

Outcomes Measured:
All three articles used the Female Sexual Function Index (FSFI) questionnaire to assess the
efficacy of Tribulus terrestris therapy in improving sexual desire. The FSFI questionnaire assesses
6 domains of female sexual function: desire, arousal, lubrication, orgasm, satisfaction, and pain.
Vale et al. and de Souza et al. used an additional questionnaire, the sexual quotient female (QS-F)
questionnaire, which includes 5 domains: desire, arousal/lubrication, orgasm, pain, and
satisfaction. Both surveys use Likert-type response formats and are scored from 0 to 5. Low scores
from both questionnaires indicate severe female sexual dysfunction.
Results:
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Akhatri et al. selected 67 adult women of whom 33 were randomly assigned to the
experimental group and 34 to the control group. Of the 67 women, a total of 7 discontinued the
trial because of noncompliance, loss to follow up, or withdrawn consent.5 The randomized study
was conducted in two medical centers in the Tehran Province of Iran. De Souza et al. selected 45
women for their study from which 9 were excluded: 3 withdrew because of personal reasons and
6 as a result of adverse side effects from taking the medication. This study was conducted in the
Clinic of Sexology of the Department of Gynecology and Obstetrics in Brazil. Vale et al. selected
64 women from which 24 were excluded from the study because of noncompliance or loss to
follow up. This study was conducted at the Universidade Federal de Minas Gerais in Brazil. None
of the excluded patients were used in the final analysis across all trials. Figure 1 illustrates subject
group allocations, exclusions, and completions across all 3 trials.
Figure 1: Flow chart indicating subject group allocations, exclusions and completions across all 3 trials
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All three trials used the FSFI questionnaire and reported a statistically significant (P <
0.05) increase in mean change from baseline in sexual desire when using Tribulus terrestris. De
Souza et al. and Vale et al. also reported a statistically significant (P < 0.05) increase in mean
change from baseline of the placebo group of <0.01 and 0.001 respectively. The results are
illustrated in Table 2. Data from these trials using FSFI as an outcome measure were reported as
continuous data that could not be converted to dichotomous form to further evaluate efficacy of
treatment. Vale et al. and de Souza et al. noted no statistically significant difference in the FSFI
scores between groups before treatment, with P values > 0.1 validating homogeneity. Akharti et
al. did not report on any statistical significance between groups on the FSFI before treatment.
Table 2: Efficacy of Tribulus terrestris in improving sexual desire using FSFI within groups
Study

Tribulus
terrestris Placebo
mean change from change
baseline
baseline

Akhtari et al.
De Souza et al.
Vale et al.

.84
1.6
1.59

.2
1.2
1.14

Mean P value*
from
< 0.0001+
<0.01
<0.001

P value**

N/A
<0.01
0.001

*p value of Tribulus terrestris pre and post treatment with no variance accountability
**p value of placebo pre and post treatment with no variance accountability
+variance between the two groups are accounted

Using QS-F, both de Souza et al. and Vale et al. reported a statistically significant (P <
0.05) increase in sexual desire. Vale et al. reported a QS-F score in the desire domain that
showed 70% of women who were taking Tribulus terrestris compared to 65% of women taking
placebo felt an improvement in desire, for a number needed to treat (NNT) of 20.7 A NNT of 20
means that for every 20 women treated with Tribulus terrestris, one more person will achieve the
desired outcome compared to those taking the placebo. De Souza et al. trial reported a QS-F
score in the desire domain that showed 75% of women who were taking Tribulus terrestris
compared to 50% of women taking placebo felt an improvement in desire, for a NNT of 4.6 The
results for QS-F are shown in Table 3.
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Table 3: Efficacy of Tribulus terrestris in the treatment of HSDD using QS-F
Study

CER

EER

RRI

ARI

NNT

P value

Vale et al

0.65

0.70

0.08

0.05

20

<0.01

De Souz et al

0.50

0.75

0.50

0.25

4

0.01

One adverse effect of abdominal cramping was reported in the Akhatri et al. study;
however, the group was not specified. Vale et al. did not report any side effects using the drug or
placebo within the respective groups. De Souza et al. reported nausea as a side effect, with 6
women withdrawing, 3 from the placebo group and 3 from the experimental group. Compliance
of the participants was not noted in the studies conducted by Vale et al. and de Souza et al. over
the 120-day duration of the trials.6,7 The study conducted by Ahkatri et al. reported that
participants were followed for 2 consecutive months with 3 in-person visits throughout the
length of the 4-week study.

Discussion
Flibanserin is the only drug approved by the FDA for treating HSDD for perimenopausal
women; therefore, in the absence of treatment options, homeopathic products offer alternative
therapy. Since flibanserin was approved only for perimenopausal women in the United States, its
application to all women is limited, and some associated side effects, such as somnolence,
dizziness, and insomnia, exist. All of the noted side effects are significant, as they could interfere
with its intended use of initiating and increasing sexually satisfying events.
Using three double-blind randomized controlled trials, this selective systematic analysis
reviewed the safety and efficacy of Tribulus terrestris in improving the sexual desire in women
with HSDD older than 18 years of age. Exclusion criteria were exhaustive and included both
medical and psychological conditions, medications, and other sexual dysfunctions in addition to
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HSDD. All three trials using the FSFI and QS-F questionnaires showed that in these women with
HSDD, taking Tribulus terrestris was associated with a statistically significant increase in sexual
desire. While the FSFI is a well-accepted questionnaire vetted to assess female dysfunction and is
used in numerous trials, including those that led to the FDA approval of flibanserin, QS-F is not.
QS-F was developed to specifically assess female sexual dysfunction in Brazilian women.
Therefore, the extent to which this questionnaire can be used in the United States as a treatment
outcome would need further evaluation. Also, no P values were reported in the Vale et al. and de
Souza et al. studies between the treatment and placebo groups before and after treatment that
adjusted for variance to further solidify the statistical significance of the treatment intervention.
All three studies varied in the population studied, manufacturers used, compliance
surveillance, length of drug administration, and intervention formulations. All studies were
conducted outside the United States in countries with different attitudes toward sexual health.
Akharti et al. noted that Iranian women tend to be more reserved in their sexual beliefs because of
their conservative culture, leading to over- or underestimations in sexual desire.5 Akhatri et al.
used a syrup formulation of Tribulus terrestris over 4 weeks while Vale et al. and de Souza et al.
used tablets and assessed over 120 days. Therefore, from the three studies, therapeutic treatment
lengths and formulations were not evaluated and may have contributed to the variations in
outcomes although all studies showed benefits.
The FDA does not regulate alternative products, such as herbal or nutritional supplements,
thus limiting the number of available studies undergoing rigorous scientific compliance when
measuring objective patient outcomes. Moreover, the exact mechanism of the effect of Tribulus
terrestris on increasing sexual desire is not well understood, creating another hurdle in the
number of clinical trials available. From the lower NNT of 4 obtained in the De Souza et al.
study compared to the Vale et al. study of 20 some inferences can be made on the possible effect
of Tribulus terrestris on hormones since the two study groups mainly differed in post and
premenopausal women. Postmenopausal women naturally undergo significant hormonal
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changes. The worldwide use of herbs is increasing; therefore, women will have no problems
obtaining this supplement from the market. Healthcare providers will inevitably encounter
women in the primary-care or gynecological setting seeking advice on herbal supplements for
HSDD.
Conclusion:
Tribulus terrestris may safely and effectively improve sexual desire in women with HSDD;
however, clear and concise methods and statistical analysis are needed to further investigate its
full clinical potential. The studies conducted by Vale et al and de Souza et al could have taken data
a step further to assess the true statistical significance of Tribulus terrestris intervention before and
after treatment compared to the placebo group after matching for effective variance. No serious or
life-threatening adverse reactions were reported. However, research is needed in the United States
with clearly defined and vetted patient outcome measurements appropriate for the culture of the
population. Studies using diary documentations for compliance and sexually satisfying events as
part of the measured outcome would also add great value to further research methods. Tribulus
terrestris production quality standardization is another area that if included in future studies will
help to increase confidence in its efficacy.
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